Watch Live

Tweet TWEET

Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

  Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form
  20-F

Business Wire

HYDERABAD, India -- July 12, 2013

Dr. Reddy’s Laboratories Limited (NYSE: RDY) today announced that its Annual
Report on Form 20-F, containing its annual consolidated financial statements
for the fiscal year ended 31 March, 2013, was filed with the United States
Securities and Exchange Commission on July 9, 2013.

The Annual Report on Form 20-F is also available on Dr. Reddy’s website,
www.drreddys.com, and can be accessed by selecting ‘SEC filings’ under the
‘Investors’ Section. ADS holders may also obtain a hard copy of the Annual
Report on Form 20-F at no cost, by sending a written request to the Company’s
registered office or by sending an e-mail to shares@drreddys.com.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com

Contact:

Dr. Reddy’s Laboratories Limited
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan, +91-40-49002445
rajans@drreddys.com
 
Press spacebar to pause and continue. Press esc to stop.